Abstract

ABSTRACT In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).

Highlights

  • En la última década, la relación de riesgos y beneficios de la THM se ha reevaluado principalmente en relación con el riesgo cardiovascular

  • Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy

  • when progestogen is added to estrogen replacement therapy (ERT) for 10-14 days a month

Read more

Summary

Guía Clínica

Guaschino 10, A Lanzone 11, AM Paoletti 12, N.

PRINCIPIOS GENERALES
DOSIS Y COMBINACIONES
Las contraindicaciones de THM se informan en la
EFECTOS A CORTO PLAZO DE LA THM
EFECTOS A LAGO PLAZO DE LA THM
Clasificación de niveles de evidencia
Grados de recomendaciones
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call